TP53 Mutation in Cancer
Tumor SuppressorTumor Protein P53
TP53 encodes the p53 protein, the most frequently mutated gene in human cancer. It acts as a tumor suppressor by regulating cell cycle arrest, apoptosis, and DNA repair in response to cellular stress.
What Is TP53?
TP53 is a gene that encodes the p53 protein, often called the "guardian of the genome." p53 is a transcription factor that responds to DNA damage, oncogene activation, and other cellular stresses by triggering cell cycle arrest, DNA repair, or apoptosis (programmed cell death). When TP53 is mutated, cells lose this critical checkpoint, allowing damaged DNA to accumulate and driving tumor progression.
TP53 Mutations in Cancer
TP53 is the most frequently mutated gene in human cancer, altered in approximately 50% of all tumors. Mutation frequency varies dramatically by cancer type: over 95% in high-grade serous ovarian cancer, ~80% in small cell lung cancer, ~70% in colorectal cancer, but less than 5% in thyroid carcinoma. Most TP53 mutations are missense mutations in the DNA-binding domain (hotspots at codons 175, 245, 248, 249, 273, and 282), which not only abolish tumor-suppressive function but can confer dominant-negative or gain-of-function properties.
Clinical Significance
TP53 mutation status is prognostic in many cancer types — it is associated with higher tumor grade, greater genomic instability, and worse overall survival. In some contexts (e.g., AML, myelodysplastic syndromes), TP53 mutations define a distinct clinical entity with very poor outcomes. TP53 mutations are also predictive: they confer resistance to certain chemotherapy regimens while sensitizing tumors to others.
Morphological Associations
TP53-mutant tumors tend to show distinct histological features that are detectable on H&E-stained slides. HistoAtlas quantifies these morphological differences computationally across all 33 TCGA cancer types: higher mitotic index, increased nuclear pleomorphism, altered immune infiltration patterns, and changes in stromal composition. Explore below how TP53 mutations reshape the tumor microenvironment in each cancer type.
Frequently Asked Questions
What is a TP53 mutation?
A TP53 mutation is a change in the DNA sequence of the TP53 gene that alters or inactivates the p53 protein. Since p53 normally prevents damaged cells from proliferating, losing p53 function allows cancer cells to grow unchecked. TP53 is the most commonly mutated gene in human cancer.
What cancers have TP53 mutations?
TP53 mutations are found across virtually all cancer types but are most frequent in ovarian serous carcinoma (>95%), small cell lung cancer (~80%), colorectal cancer (~60%), and pancreatic cancer (~70%). They are less common in thyroid cancer, kidney cancer, and testicular germ cell tumors.
Is TP53 mutation hereditary?
Most TP53 mutations in cancer are somatic (acquired during a person's lifetime). However, inherited (germline) TP53 mutations cause Li-Fraumeni syndrome, a rare hereditary condition that dramatically increases the risk of developing multiple types of cancer at a young age.
Does TP53 mutation affect survival?
In many cancer types, TP53 mutations are associated with worse overall survival and higher-grade disease. However, the prognostic impact varies by cancer type and the specific type of TP53 alteration. HistoAtlas provides survival curves comparing TP53-mutant vs wild-type tumors across 33 cancer types.